Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
3/26/2025 | $68.00 → $71.00 | Neutral → Overweight | Analyst |
3/5/2025 | Buy → Neutral | Seaport Research Partners | |
8/8/2024 | $90.00 → $89.00 | Underweight → Neutral | JP Morgan |
4/11/2024 | $100.00 → $112.00 | Equal Weight → Overweight | Wells Fargo |
3/14/2024 | $100.00 → $126.00 | Hold → Buy | Jefferies |
3/1/2024 | $108.00 | Outperform | Wolfe Research |
6/29/2023 | Outperform → In-line | Evercore ISI | |
6/26/2023 | $109.00 → $90.00 | Outperform → Market Perform | BMO Capital Markets |
Turnspire Capital Partners LLC ("Turnspire") announced today that an affiliate has completed the acquisition of Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), the former nutraceuticals business of Ashland Inc. (NYSE:ASH). Additionally, Turnspire Operating Partner Maurice Murphy has been appointed Executive Chairman, and Jeff Rogers has been appointed Interim Chief Executive Officer of Pharmachem. Pharmachem is a leading provider of proprietary nutrition ingredients and custom formulation services that supplies a broad portfolio of both active ingredients and formulation aids to nutritional product companies. The Company also offers custom formulation and contract manufactu
Pharmachem Innovations, LLC ("Pharmachem" or the "Company"), a leading provider of nutraceuticals products and solutions, today announced its launch as an independent company, following the acquisition of the Company from Ashland, Inc. (NYSE:ASH) by Turnspire Capital Partners LLC ("Turnspire"). Headquartered in Kearny, NJ, Pharmachem has a long history of working closely with customers around the world to develop and produce a wide range of specialized nutraceuticals. From its manufacturing facilities in New Jersey and Utah in the United States and Tamaulipas, Mexico, Pharmachem produces a wide range of proprietary and private labeled products used in many applications, including hydratio
WILMINGTON, Del., May 08, 2024 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) is announcing the appointment of Ashish K. Kulkarni to its Board of Directors. Kulkarni is the CEO of Kebotix, a startup company focused on commercializing artificial intelligence methods into new material commercialization. He is the former executive vice president and chief innovation officer, GAF, former chief technology and innovation officer, Avantor and former chief technology and innovation officer, Celanese Corporation. He will serve on the Board's Environmental, Health, Safety and Quality, and Compensation Committees, effective May 6, 2024. Prior to Celanese, Kulkarni held leadership positions at United Te
4 - ASHLAND INC. (0001674862) (Issuer)
4 - ASHLAND INC. (0001674862) (Issuer)
4 - ASHLAND INC. (0001674862) (Issuer)
4 - ASHLAND INC. (0001674862) (Issuer)
4 - ASHLAND INC. (0001674862) (Issuer)
WILMINGTON, Del., March 28, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) is hosting an Innovation Day for analysts and investors at the company's Bridgewater, New Jersey facility, Thursday, May 29, 2025. The event will showcase the enhanced capabilities and expanded applications of Ashland's scalable technology platforms. Registration is required, with options to attend via live webcast or in person. Participants will join Ashland's executive and senior technology team for an in-depth review of the latest developments and their expanding commercial opportunities. The presentations will detail how these advancements are poised to impact key markets and drive future growth. Following
Wilmington, Del., March 17, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that it has completed the sale of its Avoca business to Mane effective March 14, 2025. Financial terms of the transaction were not disclosed. The Avoca business supplies sclareolide, a fragrance fixative, and a range of contract manufacturing capabilities from two production facilities in North Carolina and Wisconsin. The Avoca business line represents the last entity from Ashland's previous acquisition of Pharmachem. "The Avoca business is a strong player in the fragrance fixative space, with a dedicated team and attractive manufacturing capabilities to meet customer needs," said Guillermo Novo
Sales of $405 million, down 14 percent from the prior-year quarterPreviously announced carboxymethylcellulose (CMC), methylcellulose (MC) and nutraceuticals portfolio optimization initiatives (collectively, "Portfolio Optimization") reduced overall sales by approximately $50 million or 11 percent versus the prior-year quarter. Excluding Portfolio Optimization, sales declined 3 percent versus prior-year quarterLoss from continuing operations of $166 million, or loss of $3.51 per diluted shareAdjusted income from continuing operations excluding intangibles amortization expense of $14 million, or $0.28 per diluted shareNet loss of $165 million, or loss of $3.50 per diluted shareA
SC 13G - ASHLAND INC. (0001674862) (Subject)
SC 13G/A - ASHLAND INC. (0001674862) (Subject)
SC 13D/A - ASHLAND INC. (0001674862) (Subject)
SCHEDULE 13D/A - ASHLAND INC. (0001674862) (Subject)
10-Q - ASHLAND INC. (0001674862) (Filer)
8-K - ASHLAND INC. (0001674862) (Filer)
Wilmington, Del., March 17, 2025 (GLOBE NEWSWIRE) -- Ashland Inc. (NYSE:ASH) announced today that it has completed the sale of its Avoca business to Mane effective March 14, 2025. Financial terms of the transaction were not disclosed. The Avoca business supplies sclareolide, a fragrance fixative, and a range of contract manufacturing capabilities from two production facilities in North Carolina and Wisconsin. The Avoca business line represents the last entity from Ashland's previous acquisition of Pharmachem. "The Avoca business is a strong player in the fragrance fixative space, with a dedicated team and attractive manufacturing capabilities to meet customer needs," said Guillermo Novo
Sales of $405 million, down 14 percent from the prior-year quarterPreviously announced carboxymethylcellulose (CMC), methylcellulose (MC) and nutraceuticals portfolio optimization initiatives (collectively, "Portfolio Optimization") reduced overall sales by approximately $50 million or 11 percent versus the prior-year quarter. Excluding Portfolio Optimization, sales declined 3 percent versus prior-year quarterLoss from continuing operations of $166 million, or loss of $3.51 per diluted shareAdjusted income from continuing operations excluding intangibles amortization expense of $14 million, or $0.28 per diluted shareNet loss of $165 million, or loss of $3.50 per diluted shareA
WILMINGTON, Del., Jan. 20, 2025 (GLOBE NEWSWIRE) -- The board of directors of Ashland Inc. (NYSE:ASH) has declared a quarterly cash dividend of $0.405 cents per share on the company's common stock. The dividend is payable on March 15, 2025, to stockholders of record at the close of business on March 1, 2025. As of December 31, 2024, there were 47,182,862 shares of Ashland common stock outstanding. About Ashland Ashland Inc. (NYSE:ASH) is a global additives and specialty ingredients company with a conscious and proactive mindset for environmental, social and governance (ESG). The company serves customers in a wide range of consumer and industrial markets, including architectural coatings,
Analyst upgraded Ashland from Neutral to Overweight and set a new price target of $71.00 from $68.00 previously
Seaport Research Partners downgraded Ashland from Buy to Neutral
JP Morgan upgraded Ashland from Underweight to Neutral and set a new price target of $89.00 from $90.00 previously